Local antibiotics for community acquired pneumonia
Treatments studied
Part of Immune system & allergy, Infections, Lungs & breathing clinical trials.
This trial tests whether giving antibiotics directly into the lungs can help treat severe pneumonia. If you have been hospitalized with pneumonia and have a high fever or high inflammation levels, you may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been admitted to the hospital within the last 24 hours
- You have a new chest infection confirmed by x-ray and symptoms like fever, cough, or trouble breathing
- Your pneumonia severity score (CURB-65) is 3 to 5
- You have a fever above 38.0°C or high inflammation levels (CRP above 50)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding NRICM102, a traditional Chinese medicine, to standard antibiotic treatment helps hospitalized patients with community-acquired pneumonia (a lung infection acquired outside a hospital) recover better. You would receive the herbal medicine by mouth along with your regular antibiotics.
This study watches how well the antibiotic lefamulin works in real-life patients with community-acquired pneumonia. It helps doctors understand the drug's safety and effectiveness outside of a controlled research setting.
This trial compares different antibiotic strategies for children with pneumonia who are being treated as outpatients. The goal is to find the best approach to treat the infection and help your child recover.
This trial tests a new medicine (OPT101) for people hospitalized with pneumonia and sepsis—where a lung infection causes body-wide inflammation and low oxygen. It aims to help patients who need extra oxygen but are not yet on a breathing machine.
This trial compares how long antibiotics should be given to people hospitalized with moderately severe community-acquired pneumonia. It uses your early improvement to see which antibiotic duration works best and safely.
This trial tests a new drug called SR1375 for adults with severe community-acquired pneumonia (a lung infection) who are not improving with standard antibiotics. It may help reduce inflammation and speed up recovery.
Hear when a new Community Acquired Pneumonia (CAP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.